Evidence map›Paper›PMID 38112066›Full record

ReviewExpert review of neurotherapeutics2023

Considerations for hormonal therapy in migraine patients: a critical review of current practice.

Romy van Lohuizen, Jakob Paungarttner, Christian Lampl, Antoinette MaassenVanDenBrink, Linda Al-Hassany

Open access · hybridAbstract readReview
In one paragraph

Review in Expert review of neurotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Inhibition of the METTL3/mThe journal of headache and pain · 2025
    Article
  3. Review
  4. Review
  5. Sexual Dimorphism in Migraine. Focus on Mitochondria.Current pain and headache reports · 2025
    Review
  6. Article
  7. Women in Dental Clinical and Translational Research.Advances in dental research · 2024
    Article
  8. Female-selective mechanisms promoting migraine.The journal of headache and pain · 2024
    Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Romy van LohuizenDivision of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
Jakob PaungarttnerHeadache Medical Center Linz, Linz, Austria.
Christian LamplHeadache Medical Center Linz, Linz, Austria.
Antoinette MaassenVanDenBrinkDivision of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
Linda Al-HassanyDivision of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
Erasmus MC · NLConvent Hospital of the Brothers of Saint John of God · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMigraine, a neurovascular headache disorder, is a leading cause of disability worldwide. Within the multifaceted pathophysiology of migraine, hormonal fluctuations play an evident triggering and exacerbating role, pointing toward the need for identification and proper usage of both existing and new hormonal targets in migraine treatment. AREAS COVERED: With a threefold higher incidence of migraine in women than in men, the authors delve into sex hormone-related events in migraine patients. A comprehensive overview is given of existing hormonal therapies, including oral contraceptives, intrauterine devices, transdermal and subcutaneous estradiol patches, gnRH-agonists, oral testosterone, and 5α reductase inhibitors. The authors discuss their effectiveness and risks, noting their suitability for different patient profiles. Next, novel evolving hormonal treatments, such as oxytocin and prolactin, are explored. Lastly, the authors cover hormonal conditions associated with migraine, such as polycystic ovary syndrome, endometriosis, and transgender persons receiving gender affirming hormone therapy, aiming to provide more personalized and effective solutions for migraine management. EXPERT OPINION: Rigorous research into both existing and new hormonal targets, as well as the underlying pathophysiology, is needed to support a tailored approach in migraine treatment, in an ongoing effort to alleviate the impact of migraine on individuals and society.

Indexed as

Femalesmalesmenopausemenstruationmigrainepharmacologysex hormonestreatment

Identifiers

PMID38112066
PMCPMC10791067
OpenAlexW4389958364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.